Nasser H. Hanna
Expertise in
20
conditions

Dr. Nasser H. Hanna

Oncology
Univ. Radiation Oncology Associates Inc.
535 Barnhill Dr, 
Indianapolis, IN 
Accepting New Patients
Expertise in
20
conditions
Univ. Radiation Oncology Associates Inc.
535 Barnhill Dr, 
Indianapolis, IN 

Overview

Nasser Hanna is an Oncologist practicing medicine in Indianapolis, Indiana.

Dr. Hanna is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Testicular Cancer, Teratoma of the Mediastinum, and Orchiectomy.

He is actively involved in clinical research, co-authoring 156 peer reviewed articles and participating in 7 clinical trials. Dr. Hanna is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in IN

Hospital Affiliations

Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health North Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Univ. Radiation Oncology Associates Inc.
535 Barnhill Dr, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2026
Intervention Type: Drug
Study Drugs: Osimertinib, Ramucirumab
Study Phase: Phase 2
A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Imprime PGG, MK-3475
Study Phase: Phase 1/Phase 2
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
Enrollment Status: Active_not_recruiting
Publish Date: January 02, 2026
Intervention Type: Drug
Study Drugs: Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Study Phase: Phase 2
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
Enrollment Status: Terminated
Publish Date: February 13, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
Enrollment Status: Terminated
Publish Date: March 01, 2023
Intervention Type: Drug
Study Drugs: Carboplatin, Pemetrexed, Atezolizumab, Bevacizumab
Study Phase: Phase 2
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
Understanding the Molecular and Genetic Differences Between GCT at the Time of the Initial Diagnosis and at Late Relapse
Understanding the Molecular and Genetic Differences Between GCT at the Time of the Initial Diagnosis and at Late Relapse
Enrollment Status: Completed
Publish Date: August 08, 2018
Intervention Type: Genetic
View 6 Less Clinical Trials

155 Total Publications

HSR26-193: Integrating Print-to-Web Outreach into Mammography Workflows to Promote Lung Cancer Screening: A Feasibility Study.
HSR26-193: Integrating Print-to-Web Outreach into Mammography Workflows to Promote Lung Cancer Screening: A Feasibility Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (0.1 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lawrence Einhorn is an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Einhorn is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Mediastinal Tumor, and Orchiectomy. Dr. Einhorn is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (0.1 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathy Miller is an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Miller is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Salpingo-Oophorectomy. Dr. Miller is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

IU Health Methodist Hospital

1701 Senate Blvd, 
Indianapolis, IN 
 (1.3 miles away)
317-962-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Loehrer is an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Loehrer is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Thymic Epithelial Tumor, Colorectal Cancer, Pancreatic Cancer, Thymectomy, and Pancreaticoduodenectomy. Dr. Loehrer is currently accepting new patients.

Frequently Asked Questions about Dr. Nasser H. Hanna

How do I make an appointment with Dr. Nasser H. Hanna?

You can book an appointment with Dr. Nasser H. Hanna by calling their office at 317-944-0920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nasser H. Hanna a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nasser H. Hanna is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nasser H. Hanna specialize in?

While Dr. Nasser H. Hanna is a Oncology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Testicular Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Nasser H. Hanna participate in research or clinical trials?

Yes. Dr. Nasser H. Hanna has published 155 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Nasser H. Hanna's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nasser H. Hanna accept my insurance?

Dr. Nasser H. Hanna accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-944-0920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hanna's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 7 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile